Skjødt, M. K.
Khalid, S.
Ernst, M.
Rubin, K. H.
Martinez-Laguna, D.
Delmestri, A.
Javaid, M. K.
Cooper, C.
Libanati, C.
Toth, E.
Abrahamsen, B. http://orcid.org/0000-0002-2730-6080
Prieto-Alhambra, D.
Funding for this research was provided by:
UCB
Article History
Received: 27 November 2019
Accepted: 18 February 2020
First Online: 17 March 2020
Compliance with ethical standards
: The study protocol was approved by the ISAC ethics committee for use of CPRD data, by the SIDIAP Scientific and Ethics Committee, and for the use of the Danish Health Registries by the Danish Medicines Agency, the Danish Data Protection Agency and Statistics Denmark.
: For this type of study, formal consent is not required.
: MKS has institutional research contract with UCB and educational grant from UCB. SK has nothing to disclose. ME has institutional research contract with UCB. KHR has nothing to disclose. DML received personal fees from Amgen, Eli Lilly, Novartis, Ferrer, and Rubió. AD reports grants from UCB during the conduct of the study. MKJ received honoraria, unrestricted research grants, and travel and/or subsistence expenses from Amgen and UCB. CC received personal fees from Alliance for Better Bone Health, Amgen, Eli Lilly, GSK, Medtronic, Merck, Novartis, Pfizer, Roche, Servier, Takeda, and UCB. CL and ET are employees of UCB Pharma. BA has institutional research contracts with Novartis and UCB with funds paid to the institution and received speaker fees from Amgen and personal consultancy fees from UCB and Kyowa-Kirin UK. DPA received institutional research grants from UCB and Amgen, grant from Les Laboratoires Servier, educational grants from Johnson & Johnson, and speaker and consultancy fees paid to his department by Amgen and UCB. Janssen, on behalf of IMI-funded EHDEN and EMIF consortiums, and Synapse Management Partners have supported training programmes organized by DPA’s department and open for external participants.